 Qualigen Therapeutics Inc NASDAQ: QLGN shares are surging after highlighting posters at the American Association of Cancer Research AACR. QN-302 showed potent anti-proliferative activity in a prostate cancer cell panel and anti-tumor activity in an in vivo metastatic. 